SCHEMBL506532

SCHEMBL506532

BrCc1ccc2ocnc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 1/20 0.60
GAA P10253 1/20 0.60
KMT2A Q03164 1/20 0.60
DYRK1A Q13627 2/20 0.45
CTNNB1 P35222 4/20 0.43
WNT3A P56704 4/20 0.43
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TRPM5 Q9NZQ8 1/20 0.38
NAMPT P43490 1/20 0.35
MCHR1 Q99705 1/20 0.34
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
P2RX3 P56373 1/20 0.32
P2RX2 Q9UBL9 1/20 0.32
ESR1 P03372 1/20 0.32
LMNA P02545 1/20 0.32
CLK1 P49759 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30917349 1.00 MEN1 (0.60) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL27492628 0.85 MEN1 (0.57) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL353595 0.85 DYRK1A (0.45) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL27864688 0.81 MEN1 (0.53) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL3327038 0.81 MEN1 (0.60) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL3815218 0.81 MEN1 (0.60) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL2760570 0.81 MEN1 (0.60) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL2358986 0.81 MEN1 (0.65) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL2620971 0.81 MEN1 (0.60) MEN1ALDH1A1GAAKMT2ADYRK1A
SCHEMBL31430609 0.81 MEN1 (0.60) MEN1ALDH1A1GAAKMT2ADYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 US disclosed
WO-2025124698-A1 ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-19 WO disclosed
CN-118047780-A Quinazoline heterocyclic compound and anti-infection and anti-tumor application thereof 中国医学科学院药物研究所 2024-05-17 CN disclosed
WO-2024044098-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-29 WO disclosed
EP-4289838-A2 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2023-12-13 EP disclosed
EP-3668881-B1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
EP-3599236-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2023-08-23 EP disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 US disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 US disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 US disclosed
EP-0805802-B1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE POULENC RORER LTD (GB) 2000-08-16 EP disclosed
US-6048893-A Substituted phenyl compounds with a substituent having A 1,3-benzodioxole ring RHONE-POULENC RORER LIMITED (GB) 2000-04-11 US disclosed
EP-0971895-A1 HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR AstraZeneca AB (SE) 2000-01-19 EP disclosed
WO-1998043959-A1 HYDROXAMIC ACIDS SUBSTITUTED BY HETEROCYCLES USEFUL FOR INHIBITION OF TUMOR NECROSIS FACTOR ZENECA LIMITED (GB) 1998-10-08 WO disclosed
EP-0805802-A1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE-POULENC RORER LIMITED (GB) 1997-11-12 EP disclosed
WO-1996022978-A1 SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS RHONE POULENC RORER LIMITED (GB) 1996-08-01 WO disclosed
EP-0165649-B1 FLUOROPOLYETHER COMPOUNDS Montedison S.p.A. (IT) 1990-04-18 EP disclosed
US-4889939-A LUBRICANTS MONTEDISON S.P.A. (IT) 1989-12-26 US disclosed
US-4757145-A Gives coordination bonds with metallic, polymeric, and ceramic materials MONTEDISON S.P.A. (IT) 1988-07-12 US disclosed
EP-0165649-A2 Fluoropolyether compounds Montedison S.p.A. (IT) 1985-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C9, SSB, C1S MEN1 498/4885ALDH1A1 3835/4885GAA 2718/4885
US-11725000-B2 Apoptosis inhibitors BAX, SDHA, SDHB MEN1 4080/4885ALDH1A1 550/4885GAA 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.